title: Utility of βhCG monitoring in the follow-up of medical management of miscarriage.
abstract: OBJECTIVE
  To evaluate the percentage change in total βeta-unit human chorionic gonadotropin (βhCG) levels (%ΔβhCG) in the prediction of treatment outcomes following intravaginal misoprostol for missed miscarriage before 13 weeks.
  
  
  METHODS
  A secondary analysis of a randomised controlled study of medical management of miscarriage was performed. Total βhCG levels were collected before misoprostol (baseline) and after a planned seven day interval (follow-up), when a transvaginal ultrasound (TVUS) reported a gestational sac as present or not. If no sac at TVUS, surgery was indicated on clinical criteria. %ΔβhCG ((baseline βhCG - follow-up βhCG)/baseline βhCG × 100) was evaluated in the prediction of a sac at TVUS and surgery on clinical criteria.
  
  
  RESULTS
  %ΔβhCG was calculated for cases with βhCG levels within two days of misoprostol and TVUS; calculation interval determined case number. The median %ΔβhCG for 24 cases with a persistent sac (6-9 day interval) was significantly lower than for 145 with no sac (58.75% (interquartile range (IQR): 37.59-76.69; maximum 86.54) vs 97.65% (IQR: 95.44-98.43); P < 0.0001). The median %ΔβhCG for eight cases needing surgery on clinical criteria (5-9 day interval) was significantly lower than for 140 cases with no sac not needing surgery (79.68% (IQR: 64.63-91.15; maximum 94.06) vs 97.68% (IQR: 95.61-98.50); P < 0.0001). The area under the receiver-operator curve was 0.975 for prediction of a persistent sac and 0.944 for prediction of surgery on clinical criteria, respectively. %ΔβhCG > 87% predicted no sac at TVUS. %ΔβhCG > 94.5% predicted no surgery on clinical criteria.
  
  
  CONCLUSIONS
  %ΔβhCG calculation over one week reliably predicted treatment outcomes after medical management of missed miscarriage.
authors.affiliation: Department of Obstetrics and Gynaecology, Mater Mother's Hospital, Brisbane, Queensland, Australia.|Mater Research Institute-University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Scott G
authors.initials: SG
authors.lastname: Petersen
authors.affiliation: Department of Obstetrics and Gynaecology, Mater Mother's Hospital, Brisbane, Queensland, Australia.
authors.forename: Anneliese R
authors.initials: AR
authors.lastname: Perkins
authors.affiliation: Mater Research Institute-University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Kristen S
authors.initials: KS
authors.lastname: Gibbons
authors.affiliation: Department of Obstetrics and Gynaecology, Mater Mother's Hospital, Brisbane, Queensland, Australia.
authors.forename: Julia I
authors.initials: JI
authors.lastname: Bertolone
authors.affiliation: Mater Research Institute-University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Kassam
authors.initials: K
authors.lastname: Mahomed
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use; D000030:Abortion, Missed / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D019540:Area Under Curve; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood*; D019160:Endosonography; D005260:Female; D058746:Gestational Sac / Q000000981:diagnostic imaging*; D031901:Gestational Trophoblastic Disease / Q000097:blood* / Q000175:diagnosis; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011247:Pregnancy; D012372:ROC Curve
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D018997:Chorionic Gonadotropin, beta Subunit, Human; D016595:Misoprostol
keywords: BhCG; gestational trophoblastic disease; medical management; miscarriage; misoprostol